Drugs / Varlilumab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04081688 | Sep 2019 → Apr 2022 | non-small cell lung carcinoma | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02924038 | Apr 2017 → Dec 2022 | astrocytic tumor, oligoastrocytoma, oligodendroglioma | Nicholas Butowski | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02543645 | Oct 2015 → Apr 2017 | clear cell renal carcinoma, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Celldex Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02386111 | May 2015 → Aug 2017 | clear cell renal carcinoma | Celldex Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02284971 | Nov 2014 → Apr 2016 | prostate cancer | James Larner, MD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02270372 | Nov 2014 → Jun 2016 | breast carcinoma, ovarian carcinoma | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01460134 | Oct 2011 → Dec 2015 | B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Hodgkins lymphoma, T-cell and NK-cell neoplasm +6 | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03617328 | Nov 2018 → Jan 2024 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT02413827 | Apr 2015 → Nov 2016 | metastatic melanoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02335918 | Jan 2015 → Dec 2018 | colorectal cancer, glioblastoma, head and neck squamous cell carcinoma, ovarian carcinoma +1 | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04941287 | Dec 2021 → Jan 2024 overdue | distal biliary tract carcinoma, gallbladder carcinoma, intrahepatic cholangiocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03688178 | Aug 2020 → Mar 2027 expected | glioblastoma | Annick Desjardins, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03038672 | Dec 2018 → May 2023 overdue | ALK-positive large B-cell lymphoma, Burkitt lymphoma, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type +14 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02302339 | Nov 2014 → Jun 2018 | melanoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03307746 Comparator | Nov 2017 → Feb 2021 | B-cell non-Hodgkin lymphoma | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | varlilumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02302339 ↗ |
| Known as | 1F5 | “Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62).” NCT03307746 ↗ |
| Known as | CDX-1127 | “A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer” NCT02543645 ↗5“Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62).” NCT03307746 ↗ “Varlilumab (CDX-1127)” NCT02413827 ↗ |
| Action | Activate | “varlilumab, a fully human agonist anti-CD27 mAb” PMID 35940825 ↗ Aug 2022 |
| Modality | Monoclonal antibody | “mAb” NCT02270372 ↗ |
| Route | Intravenous | “varlilumab administered IV once every 3 weeks x 3 doses” NCT02270372 ↗ |
| Target | CD27 | “specifically binds human CD27” NCT02270372 ↗ |